HealthTree

Showing 223 trials matching your filters.

A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma

The purpose of this study is to investigate if the combination of CC-486 with lenalidomide and radiation therapy is a safe and effective treatment for plasmacytoma.

DRUG: CC-486

DRUG: Lenalidomide

RADIATION: Radiation Therapy

Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refra...

This Phase 1, first-in-human (FIH), clinical study of CC-92328 will explore the safety, tolerability and preliminary biological and clinical activity of CC-92328 as a single-agent in the setting of relapsed and/or refractory multiple myeloma (R/R MM)...

DRUG: CC-92328

Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myel...

The purpose of this study is to assess safety, efficacy, pharmacokinetic (PK)/pharmacodynamic (PD), and immunogenicity with ISB 1342 in subjects with relapsed/refractory multiple myeloma.

BIOLOGICAL: ISB 1342

Home Based Daratumumab Administration for Patients With Multiple Myeloma

This clinical trial tests the treatment effect of home based daratumumab administration in treating patients with multiple myeloma. Darzalex Faspro is a combination of two drugs (daratumumab and hyaluronidase) used to treat adults with multiple myelo...

DRUG: Daratumumab and Hyaluronidase-fihj

OTHER: Questionnaire Administration

OTHER: Quality-of-Life Assessment

OTHER: Interview

Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or R...

This phase II trial studies the effect of selinexor when combined with carfilzomib, daratumumab, and dexamethasone in treating patients with high-risk multiple myeloma that has come back (recurrent) or has not responded to treatment (refractory) and ...

DRUG: Carfilzomib

BIOLOGICAL: Daratumumab

DRUG: Dexamethasone

OTHER: Quality-of-Life Assessment

DRUG: Selinexor

A Study of GC012F, a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Mult...

This trial is a phase 1b/2, open-label, multicenter study of GC012F, a CD19/BCMA dual CART-cell therapy, in adult subjects with relapsed/refractory Multiple Myeloma.

BIOLOGICAL: GC012F

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy ...

Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenance and then registered to Reg Step 2 (first randomization). Patients are randomized between Lenalidom...

DRUG: Lenalidomide

DRUG: Daratumumab/rHuPH20

Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or P...

To explore the use of curcumin and piperine supplementation at a dose of 4 gram/5mg twice a day in early stage prostate cancer patient undergoing active surveillance or patients on observation for MGUS/ low-risk smoldering myeloma.

DRUG: Curcumin plus Piperine

Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM

This is a single center, open-label, phase 2 study in elderly (age ≥ 70) subjects with newly diagnosed multiple myeloma who are transplant ineligible. Subjects will receive subcutaneous daratumumab, dose-attenuated bortezomib, revlimid, and dexametha...

DRUG: Daratumumab

DRUG: Bortezomib

DRUG: Lenalidomide

DRUG: Dexamethasone

DRUG: Ixazomib

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or, fludarabine/busulfan for patients unable to receive further radiation). followed by...

BIOLOGICAL: HSCT with TBI Regimen

BIOLOGICAL: HSCT with Non-TBI Regimen

A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With...

The purpose of this study is to test the safety and efficacy of the study drug daratumumab, when given together with Pomalidomide, Dexamethasone, and All-Transretinoic Acid (ATRA).

DRUG: Daratumumab

DRUG: Pomalidomide

DRUG: All-trans retinoic acid

DRUG: Dexamethasone

SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer

This phase 2 trial studies the immune response to GEO-CM04S1 (previously designated as COH04S1) compared to standard of care (SOC) mRNA SARS-COV-2 vaccine in patients with blood cancer who have received stem cell transplant or cellular therapy. GEO-...

BIOLOGICAL: COVID-19 Vaccine

OTHER: Diagnostic Laboratory Biomarker Analysis

BIOLOGICAL: Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1

TriPRIL CAR T Cells in Multiple Myeloma

This research study involves the study of TriPRIL CAR T Cells for treating people with relapsed or refractory multiple myeloma and to understand the side effects when treated with TriPRIL CAR T Cells. This research study involves the study drugs:. ...

DRUG: TriPRIL CAR T Cells

DRUG: Cyclophosphamide

DRUG: Fludarabine

Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With...

The purpose of this study is to identify the recommended Phase 2 dose(s) (RP2Ds) and schedule assessed to be safe for Teclistamab and to characterize the safety and tolerability of Teclistamab at the RP2Ds.

DRUG: Teclistamab (IV)

DRUG: Teclistamab(SC)

Repeated HBO Therapy in Myeloma Patients Undergoing High-Dose Therapy and Auto-HCT

Subjects with multiple myeloma (MM) who are considered eligible for high-dose therapy and autologous stem cell transplantation by the transplant team at WCI will be enrolled in the study.

DRUG: Hyperbaric oxygen

A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multipl...

This is a single-center, non-randomized, phase 2 study in which patients will receive daratumumab (subcutaneous, SC) in combination with clarithromycin/pomalidomide/dexamethasone (D-ClaPd) until progressive disease (PD) or unacceptable toxicity. This...

DRUG: Daratumumab SC

DRUG: Clarithromycin

DRUG: Pomalidomide

DRUG: Dexamethasone

Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Ce...

The purpose of this study is to see if iberdomide is a safe and effective maintenance therapy option for people with Multiple Myeloma (MM) who have had an Autologous Hematopoietic Stem Cell Transplant (AHCT) and have already had lenalidomide as maint...

DRUG: Iberdomide

A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnose...

This study is being done to find out whether carfilzomib, lenalidomide, and dexamethasone (KRD) or KRD and Daratumumab (KRD+DARA) might be safer and more effective ways of controlling multiple myeloma than the stand or care treatment, which is lenali...

DRUG: Bortezomib

DRUG: Dexamethasone

DRUG: Lenalidomide

DRUG: Acetaminophen

DRUG: Diphenhydramine

DRUG: Montelukast

DRUG: Carfilzomib

DRUG: Daratumumab

BIOLOGICAL: Autologous Stem Cell Transplant (ASCT)

Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma

This is a first in human, phase 1, multicenter, open-label study to determine the safety and tolerability of IGM-2644 as a single agent in participants with relapsed and/or refractory MM, for whom standard therapy does not exist, has proven to be ine...

DRUG: IGM-2644

High Dose Ascorbic Acid for Plasma Cell Disorders

This is a Phase I single-arm open-label clinical study primarily assessing the safety and secondarily, the relative efficacy of low dose melphalan + high dose ascorbate acid (HDAA) in relapsed refractory patients with multiple myeloma.

OTHER: Ascorbate

DRUG: Melphalan

A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma

The purpose of this study is to evaluate the safety and preliminary efficacy of CC-95266 in participants with relapsed and/or refractory multiple myeloma (R/R MM).

DRUG: CC-95266

DRUG: Fludarabine

DRUG: Cyclophosphamide

DRUG: Bendamustine

A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it ...

The primary objectives of the study are: For Phase 1 * To find out if linvoseltamab is safe and well tolerated * To find out what the most appropriate dosing schedule would be for future clinical trials For Phase 2 •To find out if it works to tre...

DRUG: Linvoseltamab

Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory...

This phase I trial tests the safety, side effects, and best dose of actinium Ac 225-DOTA-daratumumab (225Ac-DOTA-daratumumab) in combination with daratumumab and indium In 111-DOTA-daratumumab (111In-DOTA-daratumumab) in treating patients with multip...

BIOLOGICAL: Actinium Ac 225-DOTA-Daratumumab

BIOLOGICAL: Daratumumab

BIOLOGICAL: Indium In 111-DOTA-Daratumumab

Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractor...

This phase II trial tests alternate doses and dosing schedules of belantamab mafodotin in treating patients with triple-class multiple myeloma that has come back (after a period of improvement) (recurrent) and/or does not respond to treatment (or tha...

BIOLOGICAL: Belantamab Mafodotin

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspirate

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

PROCEDURE: Magnetic Resonance Imaging

PROCEDURE: Positron Emission Tomography

Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myelo...

This phase II trial studies the effect of isatuximab, carfilzomib, and pomalidomide in treating patients with multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory). Isatuximab is a monoclonal antibody that may i...

DRUG: Carfilzomib

BIOLOGICAL: Isatuximab

DRUG: Pomalidomide

Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma

This is a multi-institution, open label, phase I/II study of Iberdomide, Carfilzomib, and dexamethasone (KID) in patients with newly diagnosed transplant eligible MM.

DRUG: Carfilzomib

DRUG: Iberdomide

DRUG: Oral Dexamethasone

A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Mul...

The purpose of this study is to find out whether combination treatment with the study drugs belantamab mafodotin, nirogacestat, and pomalidomide is a safe treatment for people who have relapsed or refractory multiple myeloma. The researchers will tes...

DRUG: Belantamab Mafodotin

DRUG: Nirogacestat

DRUG: Pomalidomide

A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refract...

This is a single-arm, open-label study evaluating the safety, tolerability and efficacy of Iberdomide (CC-220) in combination with Elotuzumab and Dexamethasone in patients with RRMM. The researchers hypothesize that the combination of Iberdomide and ...

DRUG: Iberdomide

DRUG: Elotuzumab

DRUG: Dexamethasone

FT576 in Subjects With Multiple Myeloma

This is a Phase I dose-finding study of FT576 as monotherapy and in combination with the monoclonal antibody daratumumab in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage.

DRUG: FT576 (Allogenic CAR NK cells with BCMA expression)

DRUG: Cyclophosphamide

DRUG: Fludarabine

DRUG: Daratumumab

DRUG: Bendamustine

A Study of Romosozumab in Women With Multiple Myeloma and Osteoporosis

The purpose of this study is to measure the effect of romosozumab on bone formation and breakdown (resorption) and determine if romosozumab is a safe treatment for osteoporosis and myeloma-related bone disease (MBD) in postmenopausal people with mult...

DRUG: Romosozumab

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the ...

This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells...

DRUG: Bortezomib

BIOLOGICAL: Daratumumab and Hyaluronidase-fihj

DRUG: Dexamethasone

DRUG: Lenalidomide

OTHER: Quality-of-Life Assessment

Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refract...

The investigators want to find out whether or not giving patients who have relapsed or refractory multiple myeloma (MM) the experimental medication combination iberdomide, carfilzomib, daratumumab, and dexamethasone (Iber-KDd) may produce better resu...

DRUG: Iberdomide

DRUG: Carfilzomib

DRUG: Daratumumab

DRUG: Dexamethasone

DRUG: Acetaminophen

DRUG: Diphenhydramine

DRUG: Montelukast

A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Fu...

The purpose of this study is to assess the pharmacokinetics (PK), safety, and tolerability of belantamab mafodotin monotherapy in Relapsed/Refractory Multiple Myeloma (RRMM) participants with impaired hepatic function and in matched RRMM participants...

DRUG: Belantamab mafodotin

Ixazomib + Pomalidomide + Dexamethasone In MM

This is a Phase I/II study using the combination of twice weekly ixazomib plus pomalidomide and dexamethasone in relapsed and or refractory multiple myeloma (RRMM) patients.

DRUG: Ixazomib

DRUG: Pomalidomide

DRUG: Dexamethasone

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/...

This study will evaluate the efficacy and safety of belantamab mafodotin in combination with pomalidomide and dexamethasone (Arm A) compared with that of combination of pomalidomide, bortezomib and dexamethasone (Arm B) in participants with relapsed/...

DRUG: Belantamab mafodotin

DRUG: Pomalidomide

DRUG: Dexamethasone

DRUG: Bortezomib

Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Evaluate the efficacy and safety of Belantamab Mafodotin, cyclophosphamide, and dexamethasone in patients with Relapsed/Refractory Multiple Myeloma

DRUG: Belantamab Mafodotin, Cyclophosphamide and Dexamethasone

Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Dis...

This is a treatment guideline for an unrelated umbilical cord blood transplant (UCBT) using a myeloablative preparative regimen for the treatment of hematological diseases, including, but not limited to acute leukemias. The myeloablative preparative ...

DRUG: Fludarabine

DRUG: Cyclophosphamide

RADIATION: Total Body Irradiation

DRUG: Cyclosporine A

DRUG: Mycophenylate mofetil

BIOLOGICAL: Umbilical cord blood

MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Da...

The purpose of this study is to evaluate whether the BCMA-CD3 bispecific antibody elranatamab, alone and/or in combination with the anti-CD38 monoclonal antibody, daratumumab, can provide more benefit to people with multiple myeloma compared to a com...

DRUG: Elranatamab

DRUG: Daratumumab

DRUG: Pomalidomide

DRUG: Dexamethasone

Iberdomide Maintenance Therapy in Patients With Multiple Myeloma

This study will determine the feasibility, safety and efficacy of iberdomide maintenance therapy post-autologous stem cell transplant (ASCT). Treatment will continue until disease progression or toxicity. The results from this study will inform the f...

DRUG: Iberdomide

GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies

The drug that will be investigated in the study is an antibody, GEN3014. Since this is the first study of GEN3014 in humans, the main purpose is to evaluate safety. Besides safety, the study will determine the recommended GEN3014 dose to be tested in...

BIOLOGICAL: GEN3014

DRUG: Daratumumab

The Ambient Light Multiple Myeloma Study

The aim of this multi-site randomized control trial will be is to assess the impact Systematic lighting on circadian rhythm entrainment, Inflammation, Neutropenic Fever and Symptom Burden among Multiple Myeloma Patients undergoing Autologous Stem Cel...

DEVICE: Circadian Effective Lighting

DEVICE: Circadian Ineffective Lightning (CIL)

CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple ...

This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to determine the best dose of CB-011, and to assess the ef...

BIOLOGICAL: CB-011

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with...

DRUG: KTX-1001

A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Mye...

The main aim of this study is to determine safety and tolerability of modakafusp alfa given together with daratumumab to find out the best treatment dose. Another aim of this study is to learn more about the characteristics of modakafusp alfa.

DRUG: Modakafusp Alfa

DRUG: Daratumumab

Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma

The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancer. This research study combines two different ways of fighting disease: antibodies and T cells. Antibodies are proteins that protect the body...

DRUG: CAR138 T Cells

Elimination of Minimal Residual Disease After Transplant

This is a single-center, single-arm, phase II study that will enroll multiple myeloma (MM) patients with persistent bone marrow minimal residual disease (MRD) post autologous stem cell transplant (ASCT) irrespective of the International Myeloma Worki...

DRUG: Dexamethasone

DRUG: Isatuximab

DRUG: Lenalidomide

Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple My...

A phase 1b/2, open label, multi-center, Clinical Study of Chimeric Antigen Receptor T Cells targeting BCMA in patients with relapsed and or refractory multiple myeloma.

BIOLOGICAL: zevor-cel

Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CA...

This phase II trial studies the effect of pembrolizumab in treating patients with multiple myeloma that is growing, spreading, or getting worse (progressing) on chimeric antigen receptor (CAR)-T cell therapy. Immunotherapy with monoclonal antibodies,...

BIOLOGICAL: Pembrolizumab

Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myelom...

This is a multicenter, open-label phase II study in subjects with relapsed and/or refractory multiple myeloma with at least two prior lines of therapy. The main study consists of three phases: a 28-day screening phase, treatment phase that consists o...

DRUG: Isatuximab (for run-in portion)

DRUG: Isatuximab (for expansion)

DRUG: Pomalidomide

DRUG: Elotuzumab

DRUG: Dexamethasone

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Aga...

Background: A person s tumor is studied for mutations. When cells are found that can attack the mutation in a person s tumor, the genes from those cells are studied to find the parts that make the attack possible. White blood cells are then taken fr...

DRUG: Cyclophosphamide

DRUG: Fludarabine

DRUG: Aldesleukin

BIOLOGICAL: Individual Patient TCR-Transduced PBL

DRUG: Pembrolizumab (KEYTRUDA )

Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relaps...

This study aims to evaluate alternative dosing regimens of single-agent belantamab mafodotin in participants with relapsed or refractory multiple myeloma (RRMM) to determine if an improved overall benefit/risk profile can be achieved by modifying the...

DRUG: Belantamab mafodotin

Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multip...

The study will investigate the effects of adding carfilzomib to the combination of pomalidomide and dexamethasone in sequential dose escalation cohorts in patients with relapsed or refractory multiple myeloma. This portion of the study is complete. ...

DRUG: Pomalidomide

DRUG: Carfilzomib

DRUG: dexamethasone

DRUG: Daratumumab

PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma

This is a Phase II study to determine the efficacy and safety of PHE885, a BCMA-directed CAR-T cell therapy, manufactured with a new process. The CAR-T cell therapy will be investigated as a single agent in relapsed and refractory multiple myeloma

BIOLOGICAL: PHE885

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific A...

The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to ch...

DRUG: Palbociclib

DRUG: Sunitinib

DRUG: Temsirolimus

DRUG: Trastuzumab and Pertuzumab

DRUG: Vemurafenib and Cobimetinib

DRUG: Regorafenib

DRUG: Olaparib

DRUG: Pembrolizumab

DRUG: Nivolumab and Ipilimumab

DRUG: Abemaciclib

DRUG: Talazoparib

DRUG: Atezolizumab and PHESGO

DRUG: Atezolizumab and Talazoparib

DRUG: Entrectinib

DRUG: Larotrectinib

DRUG: Tucatinib plus Trastuzumab Subcutaneous (SC)

DRUG: Futibatinib

Autologous Memory-like NK Cell Therapy With BHV-1100 (Formerly KP1237), Low Dose IL-2 in Multiple My...

This is an open-label single center Phase 1a/1b study with the primary objective of establishing the safety and exploring the efficacy of infusing the ex vivo combination product of cytokine induced memory-like (CIML) NK cells plus KP1237 and low dos...

COMBINATION_PRODUCT: CIML NK Cells plus KP1237 and low dose IL-2

A Study to Learn How Linvoseltamab (REGN5458) Will Work Compared to the Elotuzumab, Pomalidomide and...

The study is researching an experimental drug called linvoseltamab, also called REGN5458. Linvoseltamab has previously been studied by itself (without other cancer drugs) in participants who had advanced multiple myeloma that returned and needed to ...

DRUG: Linvoseltamab

DRUG: Elotuzumab

DRUG: Pomalidomide

DRUG: Dexamethasone

Post-Op Pain Control for Prophylactic Intramedullary Nailing.

Nationally, the opioid crisis has become a major epidemic with increasing mortality rates each year. Orthopedic surgeons routinely prescribe narcotics instead of NSAIDs for post-op pain control because of risk of delayed healing and nonunion due to N...

DRUG: Ketorolac

DRUG: Normal saline

DRUG: Acetaminophen

DRUG: Oxycodone Acetaminophen

DRUG: Morphine

DRUG: Hydrocodone/Acetaminophen

DRUG: Oxycodone

Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Ris...

This phase II trial studies the effects of iberdomide when given alone or in combination with dexamethasone in treating intermediate or high-risk smoldering multiple myeloma patients. Immunotherapy with iberdomide may induce changes in body's immune ...

DRUG: Dexamethasone

DRUG: Iberdomide Hydrochloride

OTHER: Quality-of-Life Assessment

Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma

This is a multicenter, open-label, phase I/II clinical study, to assess the safety, tolerability, antitumor activity, pharmacokinetics and pharmacodynamics of EOS884448 (also known as EOS-448 or GSK4428859A), alone or in combination with iberdomide w...

DRUG: EOS884448

DRUG: Iberdomide

DRUG: Dexamethasone

A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (...

The purpose of the study is to identify the safe dose(s) of a PD-1 inhibitor in combination with talquetamab or teclistamab, and to characterize the safety and tolerability of talquetamab or teclistamab when administered in combination with a PD-1 in...

DRUG: Talquetamab

DRUG: Teclistamab

DRUG: PD-1 Inhibitor

Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma

This study is a first-in-human, Phase 1/2, open label study that will evaluate safety and efficacy of ISB 1442 in relapsed/refractory multiple myeloma (R/R MM).

DRUG: ISB 1442 SC injection escalating doses

DRUG: ISB 1442 SC injection at RP2D

International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Der...

* This is a multi-center, open-label, Phase 2 treatment extension study in patients with multiple myeloma who are still benefitting from isatuximab based therapy following completion of a Phase 1, 2, or 3 parental study. * This Treatment Extension st...

DRUG: Isatuximab IV (SAR650984)

DRUG: Cemiplimab (SAR439684)

DRUG: Dexamethasone

DRUG: Lenalidomide

DRUG: Pomalidomide

DRUG: Isatuximab SC (SAR650984)

Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders

The main purpose of this study is to examine the outcome of a combined bone marrow and kidney transplant from a partially matched related (haploidentical or "haplo") donor. This is a pilot study, you are being asked to participate because you have a ...

PROCEDURE: Haploidentical Bone Marrow/Kidney

Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

The purpose of this umbrella study is to evaluate isatuximab when combined with novel agents with or without dexamethasone in participants with relapsed or refractory myeloma. Substudies 02, 03, and 06 are controlled experimental substudies. Substudi...

DRUG: Isatuximab

DRUG: Dexamethasone

DRUG: Pomalidomide

DRUG: Belantamab mafodotin

DRUG: Pegenzileukin

DRUG: SAR439459

DRUG: Belumosudil

DRUG: Evorpacept

Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradi...

This is an open-label, single-arm, phase II study to determine the safety of propylene glycol-free melphalan HCl (EVOMELA®), in combination with fludarabine and total-body irradiation-based reduced-intensity conditioning for haploidentical transplant...

DRUG: Evomela

DRUG: Fludarabine

RADIATION: Total Body Irradiation

An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and...

This study is a multi-cohort, open-label, multicenter Phase 2 study to evaluate the efficacy and safety of bb2121 in subjects with relapsed and refractory MM (Cohort 1), in subjects with MM having progressed within 18 months of initial treatment incl...

BIOLOGICAL: bb2121

DRUG: Lenalomide

A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With R...

Multiple Myeloma (MM) is a cancer of the blood's plasma cells ( blood cell). The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney f...

DRUG: ABBV-383

Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

This research study is studying the combination of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in people with relapsed and refractory multiple myeloma. Relapsed and Refractory Multiple Myeloma is the condition of returned or ...

DRUG: Daratumumab

DRUG: Carfilzomib

DRUG: Pomalidomide

DRUG: Dexamethasone

Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory M...

This is a phase 1b, open-label, dose-escalation study of STI-1492 administered by a single intravenous infusion in subjects with relapsed or refractory multiple myeloma.

BIOLOGICAL: STI-1492

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smol...

This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways ...

BIOLOGICAL: Daratumumab

DRUG: Dexamethasone

DRUG: Lenalidomide

OTHER: Quality-of-Life Assessment

OTHER: Questionnaire Administration

Outpatient Administration of Teclistamab for Multiple Myeloma

This is a phase II study to evaluate the Outpatient Administration of Teclistamab in Multiple Myeloma Patients

DRUG: Teclistamab

DRUG: Tocilizumab

Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma

This is a Phase I, first-in-human (FIH), open-label, non-randomized, multi-center study to explore the safety, tolerability, pharmacokinetics and preliminary antitumor activity of NMS-03597812 in adult patients with RRMM who have exhausted standard t...

DRUG: NMS-03597812

DRUG: NMS-03597812 + dexamethasone

Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (...

Primary Objective • Assess the safety and tolerability of low-dose lenalidomide administered by continuous subcutaneous (SC) infusion (STAR-LLD) in combination with dexamethasone and a proteasome inhibitor (PI). Secondary Objectives * To assess th...

DRUG: Lenalidomide

A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or L...

The purpose of this study is to compare maintenance therapy approaches in people with newly diagnosed multiple myeloma (MM) that has responded well to a first round of treatment. The researchers will compare giving the usual maintenance therapy (lena...

DRUG: Lenalidomide

DRUG: Daratumumab

BEHAVIORAL: Questionnaires

OTHER: Dietary Intervention

APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Mult...

This is a Phase Ib/II, open-label, multi-center study evaluating the safety, tolerability, efficacy, and PK/ Pharmacodynamics of APG-2575 in combination with Pd/DRd in patients with relapsed/refractory (RR) multiple myeloma (MM). The study consists o...

DRUG: APG-2575+ Pd

DRUG: APG-2575 + DRd

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bo...

This is a multicenter, two-stage, randomized, controlled, open-label, Phase 3 study comparing the efficacy and safety of iberdomide in combination with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in ...

DRUG: Dexamethasone

DRUG: Daratumumab

DRUG: Bortezomib

DRUG: Iberdomide

Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory...

This phase II trial studies the effect of isatuximab, carfilzomib, pomalidomide, and dexamethasone in treating patients with multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory). Isatuximab is a monoclonal anti...

DRUG: Carfilzomib

DRUG: Dexamethasone

BIOLOGICAL: Isatuximab

DRUG: Pomalidomide

Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T The...

This phase II trial tests whether pembrolizumab works to shrink tumors in patients with multiple myeloma whose cancer has come back (relapsed) or did not respond to previous treatment (refractory) with anti-BCMA CAR-T therapies. Immunotherapy with pe...

BIOLOGICAL: Pembrolizumab

COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies

Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of COM902 as monotherapy and in combination with COM701 in subjects with advanced malignancies.

DRUG: Dose escalation: COM902 monotherapy.

COMBINATION_PRODUCT: Evaluation of safety/tolerability: COM902 in combination with COM701 (both at the RDFE)

DRUG: Cohort expansion: COM902 (RDFE) monotherapy.

DRUG: Cohort expansion: COM902 in combination with COM701 (both at the RDFE).

COMBINATION_PRODUCT: Cohort expansion: Triplet combination of COM902 + COM701 + Pembrolizumab.

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MP...

This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up to 100 sub...

DRUG: LP-118

Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune ...

This study will evaluate the use of siltuximab to decrease the severity of cytokine release syndrome (CRS) and immune effector cell-associated neurological syndrome (ICANS) in patients who will receive chimeric antigen receptor (CAR) T-cell therapy f...

DRUG: Siltuximab

Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation...

The goal of this clinical research study is to learn if belantamab mafodotin (Blenrep) can help to prevent multiple myeloma (MM) from coming back after patients have had an autologous stem cell transplant (AutoSCT). The safety of this drug after tran...

DRUG: Belantamab mafodotin

Tasquinimod for the Treatment of Relapsed or Refractory Myeloma

This study is the first study of tasquinimod, an inhibitor of S100A9, in patients with multiple myeloma.

DRUG: Tasquinimod

DRUG: IRd chemotherapy

Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma

This study is for patients that have a cancer called Multiple Myeloma, monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma (SM). MGUS and SM have tumor cells that possess nearly identical properties to the cancer cells see...

BIOLOGICAL: TAA-specific CTLs

BIOLOGICAL: TAA-specific CTLs- fixed dose

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments...

The purpose of this study is to determine the Recommended Phase 2 Dose and clinical benefit of elranatamab in combination with other anti-cancer therapies in participants with multiple myeloma.

DRUG: Elranatamab + Nirogacestat

DRUG: Elranatamab + lenalidomide + dexamethasone

Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Pat...

This clinical trial investigates the effect of non-chemotherapeutic interventions in patients with multiple myeloma. Non-chemotherapeutic interventions such as physical activity and nutritional interventions (e.g., modifications in diet) have been sh...

BEHAVIORAL: Behavioral Intervention

DRUG: Beta-Adrenergic Antagonist

DRUG: Propranolol

OTHER: Quality-of-Life Assessment

OTHER: Questionnaire Administration

OTHER: Resistance Training

OTHER: Short-Term Fasting

A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomali...

This phase 3 randomized, open-label multicenter trial will compare the efficacy, safety and the impact on health-related quality of life (HR-QoL) of SPd versus EloPd in pomalidomide-naïve patients with MM who have received 1 to 4 prior anti-MM regime...

DRUG: Selinexor

DRUG: Elotuzumab

DRUG: Pomalidomide

DRUG: Dexamethasone Oral

A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With ...

This is a prospective, 2-arm (with an additional exploratory arm), open-label, multicenter study looking at the response rate of patients receiving selinexor (KPT-330), in combination with carfilzomib, daratumumab or pomalidomide. Multiple Myeloma p...

DRUG: Selinexor 60 MG

DRUG: Selinexor 80 MG

DRUG: Selinexor 100 MG

DRUG: Carfilzomib

DRUG: Pomalidomide

DRUG: Daratumumab

DRUG: Dexamethasone

Melphalan on Disease Burden Measured by Next Generation Sequencing Before AHCT (Autologous Hematopoi...

The purpose of this study is to see if Multiple Myeloma (MM) cells are sensitive to the chemotherapy used in transplant or not. The main chemotherapy agent utilized in stem cell transplant is melphalan. The study will utilize 1/10 of the dose used in...

DRUG: Evomela

DEVICE: Next Generation Sequencing

DRUG: Prochlorperazine

DRUG: Acetaminophen

DRUG: Diphenhydramine

Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy

The purpose of the study is to find a safe dose and to evaluate the safety and tolerability of the drug BMS-986345, in combination with duvelisib.

DRUG: BMS-986345

DRUG: Duvelisib

SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM

This is a randomized, multicenter, Phase 3, open-label study evaluating subcutaneous (SC) vs intravenous (IV) administration of isatuximab in combination with pomalidomide and dexamethasone (Pd) in RRMM patients (study participants) who have received...

DRUG: Isatuximab IV

DRUG: Isatuximab SC

DRUG: Dexamethasone

DRUG: Pomalyst or equivalent

Ph2, Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for t...

This is a randomized, open-label study. Patients will be screened within 28 days prior to the study drug administration. Patients will be randomly assigned to 1 of 2 treatment arms prior to study drug administration. Approximately 40 patients will b...

DRUG: GPC-100

DRUG: Propranolol

DRUG: G-CSF

Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal...

This phase II trial investigates the effect of belantamab mafodotin and lenalidomide on minimal residual disease negative rates in patients with multiple myeloma with minimal residual disease positive after stem cell transplant. Belantamab mafodotin ...

BIOLOGICAL: Belantamab Mafodotin

DRUG: Lenalidomide

Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NP...

A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral covalent menin inhibitor, in adult patients with AML, ALL (with KMT2A/ MLL1r, NPM1 mutations), DLBCL, MM, and CLL/SLL.

DRUG: BMF-219

Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple M...

The purpose of this research is to determine whether the combination of selinexor, venetoclax, and dexamethasone therapy can increase anti-cancer effects in patients with translocation 11;14-positive (t(11;14)), relapsed/refractory myeloma (RRMM).

DRUG: Selinexor

DRUG: Venetoclax

DRUG: Dexamethasone

Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in T...

This phase II trial studies how well daratumumab, bortezomib, and dexamethasone followed by daratumumab, ixazomib, and dexamethasone in treating patients with multiple myeloma that has come back (relapsed) or does not response to treatment (refractor...

DRUG: Bortezomib

BIOLOGICAL: Daratumumab

DRUG: Dexamethasone

DRUG: Ixazomib

OTHER: Quality-of-Life Assessment

Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After...

To increase the conversion rate from MRD-positive to MRD-negative CR in patients with newly diagnosed multiple myeloma (NDMM) receiving post-transplant maintenance therapy with belantamab mafodotin plus lenalidomide.

DRUG: Belantamab mafodotin

DRUG: Lenalidomide

Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticoster...

This phase II trial studies the effect of immunomodulatory drug(s) in combination with a corticosteroid drug in treating patients with multiple myeloma or smoldering multiple myeloma. Immunomodulatory drugs such as lenalidomide and pomalidomide work ...

PROCEDURE: Bone Marrow Biopsy

DRUG: Dexamethasone

DRUG: Lenalidomide

DRUG: Pomalidomide

COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide

DRUG: Iberdomide

DRUG: Daratumumab

DRUG: Dexamethasone

DRUG: Carfilzomib

Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell T...

This phase I/II trial studies how well cytokine-treated veto cells work in treating patients with hematologic malignancies following stem cell transplant. Giving chemotherapy and total-body irradiation before a stem cell transplant helps stop the gro...

BIOLOGICAL: Anti-Thymocyte Globulin

DRUG: Cyclophosphamide

BIOLOGICAL: Cytokine-treated Veto Cells

DRUG: Fludarabine

PROCEDURE: Peripheral Blood Stem Cell Transplantation

RADIATION: Total-Body Irradiation

CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positi...

This phase I trial studies the side effects and best dose of CS1-chimeric antigen receptor (CAR) T therapy after chemotherapy in treating patients who have CS1 positive multiple myeloma that has come back (relapsed) or does not respond to treatment (...

PROCEDURE: CS1-CAR T Therapy

DRUG: Cyclophosphamide

DRUG: Fludarabine

PROCEDURE: Leukapheresis

A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma

The main aims of this 3-part study are as follows: Part 1: To determine any side effects from modakafusp alfa single treatment and how often they occur. The dose of modakafusp alfa will be increased a little at a time until the highest dose that doe...

DRUG: Modakafusp alfa

DRUG: Dexamethasone

Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

This phase I trial studies the side effects and best dose of MDM2 Inhibitor KRT-232 when given together with carfilzomib, lenalidomide, and dexamethasone in treating patient with multiple myeloma that has come back (relapsed) or has not responded to ...

DRUG: Carfilzomib

DRUG: Dexamethasone

DRUG: Dexamethasone Sodium Phosphate

DRUG: Lenalidomide

DRUG: Navtemadlin

Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma

This phase I study utilizes a 3+3 design with escalating cohorts of Carfilzomib at 20mg/m2, 27mg/m2, 36mg/m2, 45mg/m2, 56mg/m2, and 70mg/m2 to be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone and Granulocyte colony-stimulati...

DRUG: Carfilzomib

DRUG: Cyclophosphamide

DRUG: Dexamethasone

DRUG: Granulocyte Colony-Stimulating Factor

A Study of TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myelom...

This study will test the safety of TTI-622 in combination with daratumumab hyaluronidase-fihj in people with relapsed/refractory multiple myeloma. The researchers look for the highest dose TTI-622 that causes few or mild side effects in participants ...

DRUG: TTI-622

DRUG: Daratumumab Hyaluronidase-fihj

Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Mye...

This phase I/II trial studies the side effects and best dose of iberdomide and how well it works in combination with daratumumab, bortezomib, and dexamethasone in treating patients with newly diagnosed multiple myeloma. Immunotherapy with iberdomide,...

DRUG: Bortezomib

BIOLOGICAL: Daratumumab

DRUG: Dexamethasone

DRUG: Iberdomide

A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy

The researchers are doing this study to find out whether talquetamab is an effective treatment after BCMA CAR Tcell therapy for people with relapsed or refractory multiple myeloma. All participants in this study will have already received the BCMA CA...

DRUG: Talquetamab

Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma

The purpose of this research is to understand whether the drug metformin could be used in the future to help prevent patients with monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) from developing multipl...

DRUG: Metformin XR

OTHER: Placebo

Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM

This research is testing whether the investigational drug isatuximab is safe and effective when used in combination with standard agents for the treatment of newly diagnosed multiple myeloma.

DRUG: Isatuximab

DRUG: Lenalidomide

DRUG: Bortezomib Injection

DRUG: Dexamethasone

Descartes-25 in Relapsed/Refractory Multiple Myeloma

This is a Phase I/IIa dose-escalation study to evaluate the safety, tolerability, and preliminary efficacy of an allogeneic Mesenchymal Stem Cell (Descartes-25) product secreting a bispecific protein and other proteins in patients with Relapsed/Refra...

DRUG: Descartes-25

CART-38 in Adult AML and MM Patients

This is an open-label Phase 1 study to estimate the safety and manufacturing feasibility of lentivirally transduced T cells expressing anti-CD38 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ /4-1BB) costimulatory domains in patien...

DRUG: 3x10(6) CART-38 cellls

DRUG: 7x10(5) CART-38 cells

DRUG: 7x10(6) CART-38 cells

DRUG: 3x10(7) CART-38 cells

DRUG: Cyclophosphamide

DRUG: Fludarabine

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Ca...

The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM: SUCCESSOR-2.

DRUG: Mezigdomide

DRUG: Carfilzomib

DRUG: Dexamethasone

Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Ther...

This is a pilot study evaluating the safety and efficacy of selinexor among multiple myeloma (MM) patients that are refractory to lenalidomide-containing regimens with or without steroids.

DRUG: Selinexor

DRUG: Lenalidomide

DRUG: Methylprednisolone

A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-E...

This study will evaluate the efficacy, safety, and pharmacokinetics of cevostamab in participants with refractory multiple myeloma (R/R MM) via intravenous (IV) infusion.

DRUG: Cevostamab

DRUG: Tocilizumab

Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma

The purpose of this study is to establish the Recommended Phase 2 Dose (RP2D), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antimyeloma activity of ORIC-533 in patients with multiple myeloma who have exhausted available treat...

DRUG: ORIC-533

Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to characterize the safety of Talquetamab and to determine the recommended Phase 2 dose(s) (RP2Ds) and dosing schedule assessed to be safe for Talquetamab (Part 1 \[Dose Escalation\]) and to further characterize the safet...

DRUG: Talquetamab

Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/...

This is a phase I, multicenter, open-label, dose-escalation study of cevostamab administered as a single agent by IV infusion to participants with relapsed or refractory multiple myeloma (R/R MM).

DRUG: Cevostamab

DRUG: Tocilizumab

Myeloma-Developing Regimens Using Genomics (MyDRUG)

The MyDRUG study is a type of Precision Medicine trial to treat patients with drugs targeted to affect specific genes that are mutated as part of the disease. Mutations in genes can lead to uncontrolled cell growth and cancer. Patients with a greater...

DRUG: Abemaciclib, dexamethasone, ixazomib, pomalidomide

DRUG: Enasidenib, dexamethasone, ixazomib, pomalidomide

DRUG: Cobimetinib, dexamethasone, ixazomib, pomalidomide

DRUG: Erdafitinib, dexamethasone, ixazomib, pomalidomide

DRUG: Venetoclax, dexamethasone, ixazomib, pomalidomide

DRUG: Daratumumab, dexamethasone, ixazomib, pomalidomide

DRUG: Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide

DRUG: Selinexor, dexamethasone, ixazomib, pomalidomide

Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma

This phase II trial studies how well low-dose radiotherapy works in treating bone pain in patients with multiple myeloma that has spread to the bone. Radiation therapy uses high energy x-rays, gamma rays, neutrons, protons, or other sources to kill t...

OTHER: Quality-of-Life Assessment

OTHER: Questionnaire Administration

RADIATION: Radiation Therapy

Umbilical Cord Blood Transplantation From Unrelated Donors

This study is a single-center, treatment protocol with 4 possible preparative regimens, designed to validate the process of umbilical cord blood stem cell transplantation at our institution.

RADIATION: Total Body Irradiation 1200 cGy

RADIATION: Total Body Irradiation 200 cGy

DRUG: Cyclophosphamide

DRUG: Mesna

PROCEDURE: Cord Blood Infusion

DRUG: Busulfan

DRUG: Fludarabine

DRUG: Melphalan

Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

This is a phase II interventional study evaluating the use of minimal residual disease by next generation sequencing to defer autologous hematopoietic stem cell transplantation (AHCT) in patients with newly diagnosed multiple myeloma.

DRUG: DaraVRD

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treat...

The study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma. Linvoseltamab has previously been studied as a single agent (without other cancer treatmen...

DRUG: Linvoseltamab

DRUG: Daratumumab

DRUG: Carfilzomib

DRUG: Lenalidomide

DRUG: Bortezomib

DRUG: Pomalidomide

DRUG: Isatuximab

DRUG: Fianlimab

DRUG: Cemiplimab

DRUG: Nirogacestat

Personalized NK Cell Therapy in CBT

This phase II clinical trial studies how well personalized natural killer (NK) cell therapy works after chemotherapy and umbilical cord blood transplant in treating patients with myelodysplastic syndrome, leukemia, lymphoma or multiple myeloma. This ...

BIOLOGICAL: Allogeneic Natural Killer Cell Line NK-92

BIOLOGICAL: Anti-Thymocyte Globulin

DRUG: Busulfan

DRUG: Clofarabine

DRUG: Cyclophosphamide

DRUG: Fludarabine Phosphate

OTHER: Laboratory Biomarker Analysis

DRUG: Melphalan

BIOLOGICAL: Rituximab

RADIATION: Total-Body Irradiation

PROCEDURE: Umbilical Cord Blood Transplantation

Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple...

Doctors leading this study hope to learn if the combination of belantamab mafodotin, carfilzomib, pomalidomide, and dexamethasone is effective and safe when given to people who have multiple myeloma that has gotten worse and is not responding to stan...

DRUG: Belantamab mafodotin

DRUG: Carfilzomib

DRUG: Pomalidomide

DRUG: Dexamethasone

Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory ...

This phase Ib trial studies the side effects and best dose of isatuximab when given together with carfilzomib with or without dexamethasone and lenalidomide in treating patients with multiple myeloma that has returned after a period of improvement (r...

BIOLOGICAL: Isatuximab

DRUG: Carfilzomib

DRUG: Dexamethasone

DARA RVD For High Risk SMM

The purpose of this research study is to learn whether the combination of daratumumab SC ( Darzalex Faspro), lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone works in treating smoldering multiple myeloma and preventing progression to a...

DRUG: Daratumumab

DRUG: Bortezomib

DRUG: Lenalidomide

DRUG: Dexamethasone

A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractor...

The purpose of this study is to identify the recommended Phase 2 regimen(s) (RP2R\[s\]) and schedule for the study treatment (Part 1), to characterize the safety of the RP2R(s) for the study treatment (Part 2) and to evaluate the anticancer activity ...

DRUG: Talquetamab

DRUG: Teclistamab

DRUG: Daratumumab

A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying...

Belantamab mafodotin is an antibody-drug conjugate (ADC) containing humanized anti- B-cell maturation antigen (BCMA) monoclonal antibody (mAb). Renal impairment is a major complication of multiple myeloma (MM) and the majority of MM participants is e...

DRUG: Belantamab mafodotin

A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hem...

The purpose of this study is to see if the quality of T cells used to create ide-cel (bb2121) affects how ide-cel prevents cancer from coming back in people with relapsed or refractory multiple myeloma (MM), and who have had a hematopoietic cell tran...

BIOLOGICAL: Ide-cel (bb2121)

Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd ...

This is a randomized multicenter study that will compare two treatment regimens (Kyprolis, Revlimid, dexamethasone -KRD vs. Velcade, Revlimid, dexamethasone -VRD) for patients with newly diagnosed multiple myeloma.

DRUG: Carfilzomib

DRUG: Lenalidomide

DRUG: Dexamethasone

DRUG: Bortezomib

Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma

The purpose of this study is to see if Isatuximab can alter the immune system in patients with multiple myeloma or lymphoma upon recovery from the autologous stem cell transplantation. The investigators will see if Isatuximab makes changes to the imm...

DRUG: Isatuximab

OTHER: Standard Procedures

P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma

Phase 1 study comprised of open-label, dose escalation, multiple cohorts of P-BCMA-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed / refractory Multiple Myeloma (RRMM).

BIOLOGICAL: P-BCMA-ALLO1 CAR-T cells

DRUG: Rimiducid

Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Ris...

Background: Multiple myeloma (MM) is a tumor in which malignant plasma cells accumulate in the bone marrow. It can cause organ damage and is not curable. Researchers want to see if a combination drug treatment can help. Objective: To try to preven...

DRUG: Dexamethasone

DRUG: Carfilzomib

BIOLOGICAL: Daratumumab

Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma...

To learn if isatuximab can help to control highrisk MM when given in combination with lenalidomide after an autologous stem cell transplantation (ASCT).

DRUG: Isatuximab

DRUG: lenalidomide

Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic...

This phase Ib trial evaluates the side effects and best dose of choline salicylate given together with a low dose of selinexor in treating patients with non-Hodgkin or Hodgkin lymphoma, or multiple myeloma whose prior treatment did not help their can...

DRUG: Choline Salicylate

DRUG: Selinexor

Cevostamab Following CAR T Cell Therapy for RRMM

This is a Phase 2, open-label, single-arm, single stage, single-institution study, with an initial safety run-in period. Potential participants with relapsed/refractory myeloma who are undergoing standard of care, commercially-available BCMA-directed...

DRUG: Cevostamab

To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes o...

This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy in participants with MDS or MM who are transfusion-dependent or present with symptomati...

DRUG: INCB000928

Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion i...

Part A of this study evaluates iopofosine I 131 (CLR 131) in patients with select B-cell malignancies (multiple myeloma( MM), indolent chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL)/Waldenstrom M...

DRUG: Iopofosine I 131 single dose

DRUG: Iopofosine I 131 multiple dose

DRUG: Iopofosine I 131 fractionated dose

Personalized Autologous Transplant for Multiple Myeloma

This phase I trial studies the best dose and side effects of mephalan in treating patients with multiple myeloma who are undergoing stem cell transplant. Chemotherapy drugs, such as mephalan, work in different ways to stop the growth of cancer cells,...

PROCEDURE: Autologous Hematopoietic Stem Cell Transplantation

DRUG: Melphalan

OTHER: Questionnaire Administration

A Phase 3 Randomized, Open-label, Multicenter Study of Isatuximab (SAR650984) in Combination With Le...

Primary Objectives: * Safety run-in: To confirm the recommended dose of isatuximab when combined with lenalidomide and dexamethasone in participants with high-risk smoldering multiple myeloma (SMM) * Randomized Phase 3: To demonstrate the clinical b...

DRUG: Isatuximab SAR650984

DRUG: Lenalidomide

DRUG: Dexamethasone

Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients

This research is being done to learn whether drug called itacitinib, which is a novel inflammation- and immune-lowering drug (immunosuppressant), can be given before and after non-myeloablative peripheral blood stem cell transplantation (PBSCT; also ...

DRUG: Itacitinib

Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma

This study will evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of belantamab mafodotin in combination with Velcade (bortezomib), Revlimid (lenalidomide), dexamethasone (VRd) and will determine recommended phase 3 dose (...

DRUG: Belantamab mafodotin

DRUG: Bortezomib

DRUG: Lenalidomide

DRUG: Dexamethasone

AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Partic...

At least one dose level of AMG 176 will achieve acceptable safety and tolerability in participants with relapsed or refractory multiple myeloma and participants with relapsed or refractory acute myeloid leukemia

DRUG: AMG 176

DRUG: Azacitidine

DRUG: Itraconazole

Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual D...

To assess Minimal Residual Disease (MRD)-negative Complete Response (sCR) rate after consolidation treatment with Descartes-08 in patients with high-risk myeloma who have residual disease following induction therapy.

BIOLOGICAL: Descartes 08

Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed ...

A Phase 2, open-label, dose escalation study to evaluate the safety and efficacy of venetoclax in combination with carfilzomib-dexamethasone (Kd) in participants with relapsed or refractory MM and have received 1 to 3 prior lines of therapy. Part 4 ...

DRUG: Carfilzomib

DRUG: Venetoclax

DRUG: Dexamethasone

Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma...

The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of CFT7455 administered orally in subjects with Relapsed/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myelo...

DRUG: CFT7455

DRUG: Dexamethasone Oral

A Phase 1b/2 Study of BGB-11417in Monotherapy and in Various Combinations With Dexamethasone and Car...

Study consists of two parts, a part 1 dose escalation and a part 2 cohort expansion in combination with dexamethasone and carfilzomib intravenously across two cohorts with a monotherapy component as well.

DRUG: BGB-11417

DRUG: Dexamethasone

DRUG: Carfilzomib

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate the efficacy and safety of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3).

DRUG: Talquetamab

Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure

This phase II trial studies how well daratumumab-based therapy works in treating patients with newly diagnosed multiple myeloma with kidney failure. Daratumumab-based therapy includes daratumumab, bortezomib, dexamethasone, and thalidomide or lenalid...

DRUG: Bortezomib

BIOLOGICAL: Daratumumab

DRUG: Dexamethasone

DRUG: Lenalidomide

DRUG: Thalidomide

Allo HSCT Using RIC and PTCy for Hematological Diseases

This is a Phase II study following subjects proceeding with our Institutional non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen followed by a related, unrelated, or partially matched family donor stem ce...

BIOLOGICAL: Peripheral Blood Stem Cell Transplant

DRUG: Allopurinol 300 MG

DRUG: Fludarabine

DRUG: Cyclophosphamide

BIOLOGICAL: Bone Marrow Cell Transplant

RADIATION: Total Body Irradiation

DRUG: Sirolimus Pill

DRUG: Mycophenolate Mofetil

Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD...

This phase Ib trial tests the safety, side effects, and best dose of CC-92480 in combination with elotuzumab and dexamethasone in treating patients with multiple myeloma that has come back after a period of improvement (relapsed) or that does not res...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

DRUG: Dexamethasone

PROCEDURE: Echocardiography

BIOLOGICAL: Elotuzumab

PROCEDURE: Magnetic Resonance Imaging

BIOLOGICAL: Mezigdomide

PROCEDURE: X-Ray Imaging

Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newl...

A randomized Phase II clinical trial will be conducted to assess the impact on progression free survival (PFS) with the addition of ixazomib and daratumumab to lenalidomide as a maintenance treatment following induction with lenalidomide, ixazomib, d...

DRUG: Lenalidomide

DRUG: Ixazomib

DRUG: Daratumumab Injection

DRUG: Dexamethasone

BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma

This is a first-in-human study to evaluate the feasibility, safety and preliminary antitumor efficacy of autologous T cells genetically engineered with a novel B-cell Maturation Antigen (BCMA)-specific chimeric antigen receptor (CAR) and manufactured...

BIOLOGICAL: PHE885

Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditionin...

This randomized phase II trial includes a blood stem cell transplant from an unrelated donor to treat blood cancer. The treatment also includes chemotherapy drugs, but in lower doses than conventional (standard) stem cell transplants. The researchers...

PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation

DRUG: Cyclophosphamide

DRUG: Cyclosporine

DRUG: Mycophenolate Mofetil

DRUG: Sirolimus

A Study of MCARH109 and MCARH125 in People With Multiple Myeloma

A sample of participants' T cells will be sent to a laboratory, where the cells will be made into the study therapy, MCARH109 and MCARH125. Participants will receive either MCARH125 alone or MCARH125 with MCARH109.

BIOLOGICAL: MCARH125

BIOLOGICAL: MCARH109

Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antige...

This is a multicenter phase II, open-label study evaluating the efficacy and safety of belantamab mafodotin maintenance in participants with relapsed and/or refractory multiple myeloma (RRMM) who have received commercially available anti-BCMA CAR-T-c...

DRUG: Belantamab mafodotin

Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Tria...

This phase II trial test whether combination chemotherapy works to improve blood test results in patients with high-risk multiple myeloma. Chemotherapy drugs, such as carfilzomib, daratumumab, lenalidomide, and dexamethasone, work in different ways t...

PROCEDURE: Bone Marrow Aspiration and Biopsy

DRUG: Carfilzomib

PROCEDURE: Computed Tomography

BIOLOGICAL: Daratumumab

DRUG: Dexamethasone

DRUG: Lenalidomide

PROCEDURE: Magnetic Resonance Imaging

PROCEDURE: Positron Emission Tomography

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy D...

The purpose of this study is to compare the efficacy of Bortezomib, Lenalidomide and Dexamethasone (VRd) induction followed by a single administration of ciltacabtagene autoleucel (cilta-cel) versus VRd induction followed by Lenalidomide and Dexameth...

DRUG: Bortezomib

DRUG: Dexamethasone

DRUG: Lenalidomide

DRUG: Cilta-cel

DRUG: Cyclophosphamide

DRUG: Fludarabine

VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Le...

This phase I trial studies the best dose and side effects of recombinant vesicular stomatitis virus carrying the human NIS and IFN beta genes (VSV-hIFNbeta-sodium iodide symporter \[NIS\]) with or without cyclophosphamide or ipilimumab and nivolumab ...

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

DRUG: Cyclophosphamide

BIOLOGICAL: Ipilimumab

BIOLOGICAL: Nivolumab

PROCEDURE: Positron Emission Tomography

BIOLOGICAL: Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter

PROCEDURE: Single Photon Emission Computed Tomography

Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma

Selinexor (KPT-330, Xpovio) is a first in class selective inhibitor of nuclear export which has been approved for use in relapsed and refractory multiple myeloma (RRMM). This trial will seek to evaluate the outcomes achieved with selinexor based comb...

DRUG: Selinexor

DRUG: Pomalidomide

DRUG: Daratumumab

DRUG: Carfilzomib

DRUG: Dexamethasone

A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin...

This is a single-center, single arm, phase I study designed to determine the safety and find the recommended Phase 2 dose (RP2D) or maximum dose level (MTD) of Belantamab Mafodotin in patients with high-risk smoldering multiple myeloma. The study wil...

DRUG: Belantamab mafodotin

Immuno-PRISM (PRecision Intervention Smoldering Myeloma)

The purpose of this study is to test the anti-cancer activity of Teclistamab and to compare it with Lenalidomide + Dexamethasone combination in people with high risk smoldering multiple myeloma. People with smoldering multiple myeloma (SMM) usually ...

DRUG: Teclistamab

DRUG: Lenalidomide

DRUG: Dexamethasone

A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and...

The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP) and talquetamab SC in combination with daratumumab SC (Tal-D), respectively, with daratumumab SC in ...

DRUG: Talquetamab

DRUG: Daratumumab

DRUG: Pomalidomide

DRUG: Dexamethasone

First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL

Primary Objective: To determine the maximum tolerated dose (MTD) of SAR442257 administered as a single agent in patients with relapsed and refractory multiple myeloma (RRMM) and relapsed and refractory non-Hodgkin lymphoma (RR-NHL), and determine th...

DRUG: SAR442257

A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) ...

The main purpose of the study is to evaluate the safety and tolerability of the combination of elranatamab and carfilzomib and dexamethasone or elranatamab and maplirpacept. There are 2 parts to this study. Part 1 will evaluate the safety and tolera...

DRUG: Elranatamab

DRUG: Carfilzomib

DRUG: Maplirpacept

Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for M...

This is a single-institution, single-arm, phase 2 study in which belantamab mafodotin (GSK2857916), an antibody-drug conjugate targeting B-cell maturation antigen (BCMA), will be administered to patients with multiple myeloma prior to and following h...

DRUG: Belantamab mafodotin

A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Rel...

This Phase Ib, multicenter, open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of cevostamab monotherapy, cevostamab plus pomalidomide and dexamethasone (Pd) or cevostamab plus daratumumab and de...

DRUG: Cevostamab

DRUG: Tocilizumab

DRUG: Pomalidomide

DRUG: Daratumumab

DRUG: Dexamethasone

Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma

Master protocol for cell therapy, Phase 1 proof-of-concept studies in relapsed and refractory multiple myeloma and includes long-term safety follow-up.

DRUG: CART-ddBCMA

DRUG: ARC-T Plus Anti-BCMA SparX

A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Ca...

The purpose of this study is to compare the efficacy of teclistamab with PVd/Kd.

DRUG: Teclistamab

DRUG: Pomalidomide

DRUG: Bortezomib

DRUG: Dexamethasone

DRUG: Carfilzomib

A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma

The main aims of this study are to test for any side effects from modakafusp alfa in combination therapy and to determine the recommended dose of combination therapy with modakafusp. The dose of modakafusp alfa will be increased a little at a time un...

DRUG: Modakafusp alfa

DRUG: Lenalidomide

DRUG: Bortezomib

DRUG: Carfilzomib

DRUG: Daratumumab

DRUG: Pomalidomide

Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multipl...

The purpose of this study is to determine response rate after 8 cycles of D-KRd (daratumumab, carfilzomib, lenalidomide (Revlimid) and dexamethasone in patients with multiple myeloma.

DRUG: Daratumumab

DRUG: Carfilzomib

DRUG: Lenalidomide

DRUG: Dexamethasone

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-3...

Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and toxicity of ABBV-383 when co-administered with pomalidomide-dexamethasone (Pd)...

DRUG: ABBV-383

DRUG: Dexamethasone

DRUG: Lenalidomide

DRUG: Pomalidomide

DRUG: Nirogacestat

DRUG: Daratumumab

Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma

Selinexor is a drug that has been approved in the treatment of patients with symptomatic multiple myeloma. The standard of care for patients with Smoldering Multiple Myeloma remains observation, but there are numerous clinical trials investigating in...

DRUG: Selinexor

Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple...

The purpose of this research study is to determine if two drugs approved for treating multiple myeloma, belantamab mafodotin and elotuzumab, are safe and more effective when used together.

DRUG: Elotuzumab

DRUG: Belantamab mafodotin

MM CAR-T to Upgrade Response BMTCTN1902

This study is designed as a Phase II, multicenter, single arm trial to assess anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptor (CAR) T-cells (bb2121) to improve post autologous hematopoietic cell transplant (HCT) responses among patien...

DRUG: Lenalidomide and bb2121

Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients...

This phase I/II trial identifies the best dose and side effects of selinexor, and how well it works when given in combination with pomalidomide and dexamethasone with or without carfilzomib in treating patients with multiple myeloma that has come bac...

DRUG: Carfilzomib

DRUG: Dexamethasone

DRUG: Pomalidomide

OTHER: Quality-of-Life Assessment

OTHER: Questionnaire Administration

DRUG: Selinexor

Steroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple Myelo...

The purpose of this study is to determine the effects of daratumumab and lenalidomide without steroids for treating patients with multiple myeloma.

DRUG: Daratumumab

DRUG: Lenalidomide

DRUG: Dexamethasone

Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple ...

This phase I trial studies the side effects and best dose of selinexor and carfilzomib when given together with dexamethasone in treating patients with multiple myeloma that has returned or does not respond to treatment. Drugs used in chemotherapy, s...

DRUG: selinexor

DRUG: carfilzomib

DRUG: dexamethasone

Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Recep...

This study is a Phase II study to determine the preliminary safety and efficacy of salvage radiation treatment after BCMA CAR-T therapy in subjects with RRMM. The study population will consist of subjects with RRMM previously treated with SOC BCMA C...

DRUG: Radiation Therapy

A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) ...

The work proposed herein aims to provide the first prospective, randomized comparative efficacy data between Melphalan and BEAM treatment regimen in the Multiple Myeloma (MM) patient population. The risk of such a study is deemed reasonable and ethic...

DRUG: Allopurinol

DRUG: Carmustine

DRUG: Etoposide

DRUG: Cytarabine

DRUG: Melphalan

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Eff...

The purpose of this study is to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.

DRUG: CC-92480

DRUG: Bortezomib

DRUG: Dexamethasone

DRUG: Daratumumab

DRUG: Carfilzomib

DRUG: Elotuzumab

DRUG: Isatuximab

DRUG: Carfilzomib

Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma

Multiple myeloma (MM) is the second most common hematologic malignancy with an estimated annual incidence of nearly 35,000 cases. While still considered an incurable disease, new treatments have improved outcomes dramatically over the last two decade...

DRUG: Mezigdomide

DRUG: Ixazomib

DRUG: Dexamethasone

Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma

This phase II trial studies the effect of belantamab mafodotin, pomalidomide, and dexamethasone in treating patents with high-risk myeloma. Belantamab mafodotin is a monoclonal antibody, called belantamab, linked to a chemotherapy drug, called mafodo...

BIOLOGICAL: Belantamab Mafodotin

DRUG: Dexamethasone

DRUG: Pomalidomide

A Rollover Study of CC-122

The purpose of the study is to provide CC-122 treatment to participants who have been receiving treatment in other CC-122 clinical trials investigating CC-122 for more than 5 years (CC-122-ST-001 \[NCT01421524\], CC-122-ST-002 \[NCT02509039\], CC-122...

DRUG: CC-122

DRUG: Dexamethasone

A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma

The purpose of this study is to characterize the safety and tolerability of talquetamab when administered in different combination regimens and to identify the safe dose(s) of talquetamab combination regimens.

DRUG: Talquetamab

DRUG: Carfilzomib

DRUG: Daratumumab SC

DRUG: Lenalidomide

DRUG: Pomalidomide

Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory ...

This phase I/II trial studies the safety of the combination of bortezomib, dexamethasone, and pembrolizumab with or without pelareorep in treating patients with multiple myeloma that has come back (relapsed) or does not response to treatment (refract...

DRUG: Bortezomib

DRUG: Dexamethasone

BIOLOGICAL: Pelareorep

BIOLOGICAL: Pembrolizumab

Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell ...

Background: - In allogeneic stem cell transplantation (SCT), stem cells are taken from a donor and given to a recipient. Sometimes the recipient s immune system destroys the donor s cells. Or donor immune cells attack the recipient s tissues, called...

BIOLOGICAL: Rituximab

DRUG: Conditioning chemotherapy

DRUG: TMS

DRUG: FLAG

DRUG: EPOCH-F

PROCEDURE: Hematopoietic stem cell transplant

DRUG: Palifermin

Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple...

This is a single-arm, open-label phase II study with a safety lead-in phase.

DRUG: Bortezomib

DRUG: Isatuximab

DRUG: Cyclophosphamide

DRUG: Dexamethasone

A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relap...

Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and toxicity of ABBV-453 in adult participants with relapsed/refractory (R/R) MM. ...

DRUG: ABBV-453

DRUG: Dexamethasone

DRUG: Daratumumab

DRUG: Lenalidomide

Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multip...

This phase I trial finds out the best dose and side effects of venetoclax and tocilizumab in treating patients with t(11;14) multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory). Venetoclax may stop the growth ...

BIOLOGICAL: Tocilizumab

DRUG: Venetoclax

Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myelo...

This phase I trial studies the safety, side effects, best dose and effectiveness of mezigdomide (CC-92480) when given after idecabtagene vicleucel (Abecma chimeric antigen receptor \[CAR\] T-cell therapy) in patients with multiple myeloma that has co...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Computed Tomography

BIOLOGICAL: Mezigdomide

PROCEDURE: Positron Emission Tomography

CAR- PRISM (PRecision Intervention Smoldering Myeloma)

The goal of this research study is to test if ciltacabtagene autoleucel (cilta-cel) is safe and effective in treating participants with high-risk, smoldering myeloma. The names of the treatment interventions used in this study are: * Cilta-cel (or ...

DRUG: Ciltacabtagene Autoleucel

DRUG: Cyclophosphamide

DRUG: Fludarabine Phosphate

A Study of the Safety, Tolerability and Effectiveness of EZM0414 Investigative Product in Participan...

This study will include participants with relapsed/refractory (R/R) Multiple Myeloma (MM). MM is a type of cancer of the blood. This study will also include participants with relapsed/refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). DLBCL is ...

DRUG: EZM0414

Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant

Cancer and treatment-related cognitive changes hinder resumption of normal routine and roles and worsen quality of life. Older adults undergoing hematopoietic cell transplantation (HCT) are at high-risk for cognitive impairment. Physical activity imp...

BEHAVIORAL: CHAMPS-II adapted to adults 60+ years in HCT setting

Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Und...

This phase II clinical trial evaluates whether a modified modality of conditioning reduces treatment-related mortality (TRM) in patients who undergo a hematopoietic stem cell transplant (HSCT) for a hematological malignancy. HSCT is a curative therap...

PROCEDURE: Hematopoietic Cell Transplantation

DRUG: Mycophenolate Mofetil

DRUG: Tacrolimus

DRUG: Cyclophosphamide

RADIATION: Total-Body Irradiation

PROCEDURE: Donor Lymphocyte Infusion

DRUG: Fludarabine

DRUG: Melphalan

Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent o...

This phase I trial tests the safety, side effects and best dose of MUC1-activated T cells in treating patients with multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory) and is positive for expression of the MUC...

BIOLOGICAL: Autologous MUC1-activated T-cells

DRUG: Cyclophosphamide

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After T...

The purpose of this study is to evaluate whether elranatamab monotherapy can provide clinical benefit compared to lenalidomide monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplan...

DRUG: Elranatamab

DRUG: Lenalidomide

DRUG: Elranatamab

Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKAL...

Patients have a type of cancer called NHL, Multiple Myeloma (MM) or CLL that has come back or has not gone away after treatment. There is no standard treatment for the cancer at this time or the currently used treatments do not work completely in all...

BIOLOGICAL: Kappa CD28 T cells

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologo...

The purpose of this study is to compare the effectiveness of iberdomide maintenance to lenalidomide maintenance therapy after autologous stem cell transplantation (ASCT) in participants with newly diagnosed multiple myeloma (NDMM).

DRUG: Iberdomide

DRUG: Lenalidomide

Phase I/II Randomized Trial of Cord Blood-derived NK Cells Genetically Engineered With NY-ESO-1 TCR/...

To find the recommended dose of NY-ESO-1 TCR/IL-15 NK cells that can be given to patients with relapsed or refractory MM. To learn if the dose of NY-ESO-1 TCR/IL-15 NK cells found in Part A can help to control the disease.

DRUG: Fludarabine phosphate

DRUG: Cyclophosphamide

DRUG: NY-ESO-1 TCR/IL-15 NK

Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing...

This early phase I trial studies how well loratadine works in reducing granulocyte-colony stimulating factor (G-CSF) induced bone pain in patients with multiple myeloma who are undergoing stem cell mobilization. Loratadine is an antihistamine that ma...

DRUG: Loratadine

OTHER: Placebo

OTHER: Questionnaire Administration

Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation f...

This phase I trial studies the side effects and best dose of 211At-OKT10-B10 when given together with melphalan before a stem cell transplantation in treating patients with multiple myeloma. The radioimmunotherapy drug 211At-OKT10-B10 is a monoclonal...

BIOLOGICAL: Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10

DRUG: Melphalan

PROCEDURE: Peripheral Blood Stem Cell Transplantation

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination Wi...

The purpose of this study is to assess the safety, tolerability and preliminary effectiveness of CC-92480 (BMS-986348) in novel therapeutic combinations for the treatment of Relapsed or Refractory Multiple Myeloma (RRMM).

DRUG: CC-92480

DRUG: Tazemetostat

DRUG: BMS-986158

DRUG: Trametinib

DRUG: Dexamethasone

Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease ...

This is a phase II study where patients will undergo isatuximab and lenalidomide maintenance if they are MRD-positive after Autologous Stem Cell Transplant (ASCT)

DRUG: Isatuximab

DRUG: Lenalidomide

Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma

This research study is investigating the safety and effectiveness of using combination of isatuximab, lenalidomide and dexamethasone for the treatment of newly diagnosed multiple myeloma (MM). The study team will use lower doses than is currently sta...

DRUG: Isatuximab

DRUG: Lenalidomide

DRUG: Dexamethasone

Free From Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial) for Minimal Residual Dise...

A pilot study to assess the risk of progression after stopping post-autologous stem cell transplant (ASCT) maintenance therapy in Minimal Residual Disease (MRD)-negative MM patients.

OTHER: Discontinue maintenance therapy SOC

Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Be...

One of the ways that cancer grows and spreads is by avoiding the immune system.NK cells are immune cells that kill cancer cells, but are often malfunctioning in people with colorectal cancer and blood cancers. A safe way to give people with colorecta...

DRUG: Vactosertib

DRUG: Fludarabine Phosphate

DRUG: Cyclophosphamide

DRUG: IL-2

DRUG: Natural Killer Cells

Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma

This research study is being done to learn if the study drug belantamab mafodotin, in combination with other standard medications, can improve multiple myeloma. This study will also help determine what effects, good and/or bad, this combination of st...

DRUG: Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin

Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

This study will assess the safety, tolerability, pharmacokinetics (PK) and the therapeutic potential of HDP-101 in patients with plasma cell disorders including multiple myeloma.

DRUG: HDP-101

Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refracto...

Study CC-93269-MM-001 is an open-label, Phase 1, dose escalation (Part A and C) and expansion (Parts B and D), first-in-human clinical study of CC-93269 in subjects with relapsed and refractory multiple myeloma.

DRUG: CC-93269

Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments...

B-cell maturation antigen (BCMA) is a target present on tumor cells in participants with multiple myeloma. Belantamab mafodotin (GSK2857916); is an antibody-drug conjugate (ADC) containing humanized anti-BCMA monoclonal antibody (mAb). This is a phas...

DRUG: Belantamab mafodotin

DRUG: GSK3174998

DRUG: Feladilimab

DRUG: Nirogacestat

DRUG: Dostarlimab

DRUG: Isatuximab

DRUG: Lenalidomide

DRUG: Dexamethasone

DRUG: Pomalidomide

A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Mono...

The purpose of this study is to find out whether cyclophosphamide, bortezomib, dexamethasone (CyBorD) with daratumumab SC is a safe treatment combination for MGRS-associated kidney disease including cast nephropathy associated with multiple myeloma. ...

DRUG: Cyclophosphamide

DRUG: Bortezomib

DRUG: Dexamethasone

DRUG: Daratumumab

Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma

This is a single-arm, phase II, open-label trial to investigate the effects of selinexor (S) in combination with daratumumab, lenalidomide, and dexamethasone (DRd) for first-line treatment of multiple myeloma (MM). FDA has approved selinexor plus de...

DRUG: Selinexor

DRUG: Dexamethasone Oral

DRUG: Daratumumab

DRUG: Lenalidomide

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Tr...

This phase III trial compares three-drug induction regimens followed by double-or single-drug maintenance therapy for the treatment of newly diagnosed multiple myeloma in patients who are not receiving a stem cell transplant and are considered frail ...

DRUG: Bortezomib

DRUG: Daratumumab and Hyaluronidase-fihj

DRUG: Dexamethasone

DRUG: Lenalidomide

OTHER: Quality-of-Life Assessment

OTHER: Questionnaire Administration

A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (...

This is a phase 1, multicenter, open-label study evaluating the safety and efficacy of ruxolitinib, steroids and lenalidomide among MM patients who currently show progressive disease.

DRUG: Ruxolitinib Oral Tablet [Jakafi]

DRUG: Lenalidomide

DRUG: Methylprednisolone

Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma

This is an open-label study to determine the safety of anti-B-cell maturation antigen (BCMA) Chimeric antigen receptor T-cell (CAR T) therapy in participants with Relapsed or Refractory Multiple Myeloma (RRMM).

BIOLOGICAL: Manufactured Anti-BCMA CAR-T cells

DRUG: Fludarabine

DRUG: Cyclophosphamide

Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple My...

This phase II trial studies how well leflunomide, pomalidomide, and dexamethasone work for the treatment of multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory). Leflunomide may stop the growth of cancer cells ...

DRUG: Dexamethasone

DRUG: Leflunomide

DRUG: Pomalidomide

Teclistamab or Talquetamab in Combination With Daratumumab for High-Risk Smoldering Myeloma (REVIVE ...

The purpose of this study is to see whether combination treatment of Teclistamab and Daratumumab (Tel-Dara) or combination Talquetamab and Daratumumab (Tal-Dara) will delay the onset of multiple myeloma.

DRUG: Teclistamab

DRUG: Talquetamab

DRUG: Daratumumab SC

Study of CART-ddBMCA in Relapsed or Refractory Multiple Myeloma (iMMagine-1)

A Phase II study of CART-ddBCMA for patients with relapsed or refractory multiple myeloma. CART-ddBCMA is a BCMA-directed CAR-T cell therapy

BIOLOGICAL: CART-ddBCMA

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hemat...

This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without daratumumab or rituximab to eva...

DRUG: IDP-023

DRUG: Rituximab

DRUG: Daratumumab

DRUG: Interleukin-2

DRUG: Cyclophosphamide

DRUG: Fludarabine

DRUG: Mesna

A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma

The purpose of this study is to determine the maximum-tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of ION251 in patients with relapsed/refractory multiple myeloma.

DRUG: ION251

Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Aut...

A randomized placebo controlled, phase 2 study of budesonide in subjects with multiple myeloma undergoing autologous stem cell transplant (ACST). The study includes a run-in period with 20 patients.

DRUG: Budesonide EC

DRUG: Placebo

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezom...

The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRM...

DRUG: mezigdomide

DRUG: Pomalidomide

DRUG: Bortezomib

DRUG: Dexamethasone

Thanks to our HealthTree Community for Multiple Myeloma Sponsors:

Charity Navigator

HealthTree Foundation is a qualified 501(c)(3) tax-exempt organization.

Tax ID 45-5354811

Get the latest thought leadership on Multiple Myeloma delivered straight to your inbox.

Thanks to our HealthTree Community for Multiple Myeloma Sponsors:

Follow Us